Compare IPCA Labs with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs PROCTER & GAMBLE HEALTH - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS PROCTER & GAMBLE HEALTH IPCA LABS/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 22.9 53.0 43.3% View Chart
P/BV x 4.4 4.8 92.7% View Chart
Dividend Yield % 0.1 9.9 1.1%  

Financials

 IPCA LABS   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    IPCA LABS
Mar-18
PROCTER & GAMBLE HEALTH
Dec-18
IPCA LABS/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs6953,549 19.6%   
Low Rs4001,301 30.7%   
Sales per share (Unadj.) Rs260.2511.4 50.9%  
Earnings per share (Unadj.) Rs19.061.3 31.0%  
Cash flow per share (Unadj.) Rs33.174.0 44.7%  
Dividends per share (Unadj.) Rs1.00440.00 0.2%  
Dividend yield (eoy) %0.218.1 1.0%  
Book value per share (Unadj.) Rs213.0927.8 23.0%  
Shares outstanding (eoy) m126.2016.60 760.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.14.7 44.4%   
Avg P/E ratio x28.939.6 73.0%  
P/CF ratio (eoy) x16.632.8 50.6%  
Price / Book Value ratio x2.62.6 98.4%  
Dividend payout %5.3717.9 0.7%   
Avg Mkt Cap Rs m69,12040,257 171.7%   
No. of employees `00013.31.1 1,168.8%   
Total wages/salary Rs m7,3591,313 560.6%   
Avg. sales/employee Rs Th2,477.47,486.7 33.1%   
Avg. wages/employee Rs Th555.21,157.6 48.0%   
Avg. net profit/employee Rs Th180.6897.2 20.1%   
INCOME DATA
Net Sales Rs m32,8368,490 386.8%  
Other income Rs m418244 171.4%   
Total revenues Rs m33,2548,734 380.7%   
Gross profit Rs m4,5051,482 304.0%  
Depreciation Rs m1,777211 841.5%   
Interest Rs m2400-   
Profit before tax Rs m2,9051,514 191.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m511563 90.9%   
Profit after tax Rs m2,3941,017 235.3%  
Gross profit margin %13.717.5 78.6%  
Effective tax rate %17.637.1 47.4%   
Net profit margin %7.312.0 60.8%  
BALANCE SHEET DATA
Current assets Rs m19,45515,343 126.8%   
Current liabilities Rs m10,0761,960 514.0%   
Net working cap to sales %28.6157.6 18.1%  
Current ratio x1.97.8 24.7%  
Inventory Days Days9849 200.9%  
Debtors Days Days6728 235.3%  
Net fixed assets Rs m20,2601,209 1,675.3%   
Share capital Rs m252166 152.0%   
"Free" reserves Rs m26,63315,235 174.8%   
Net worth Rs m26,88615,401 174.6%   
Long term debt Rs m2,3400-   
Total assets Rs m41,17317,595 234.0%  
Interest coverage x13.1NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x0.80.5 165.3%   
Return on assets %6.45.8 110.7%  
Return on equity %8.96.6 134.8%  
Return on capital %10.810.3 104.9%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,6421,636 955.9%   
Fx outflow Rs m4,8844,368 111.8%   
Net fx Rs m10,759-2,732 -393.8%   
CASH FLOW
From Operations Rs m3,411-1,304 -261.6%  
From Investments Rs m-1,35412,697 -10.7%  
From Financial Activity Rs m-1,304-301 434.0%  
Net Cashflow Rs m75311,093 6.8%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 11.4 18.2 62.6%  
FIIs % 25.3 1.0 2,530.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 29.1 59.8%  
Shareholders   36,892 28,591 129.0%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PLETHICO PHARMA  BIOCON   J.B.CHEMICALS  ALKEM LABORATORIES  AJANTA PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

ABBOTT INDIA at All Time High; BSE HEALTHCARE Index Up 0.4% (Market Updates)

Sep 16, 2019 | Updated on Sep 16, 2019

ABBOTT INDIA share price has hit an all time high at Rs 10,015 (up 1.5%). The BSE HEALTHCARE Index is up by 0.4%. Among the top gainers in the BSE HEALTHCARE Index today are ABBOTT INDIA (up 1.5%) and PROCTER & GAMBLE HEALTH (up 1.2%). The top losers include NATCO PHARMA (down 0.2%) and BIOCON (down 0.2%).

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 16, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS